Carbamic acid, N-[1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester | 1279834-93-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Carbamic acid, N-[1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester
• 英文别名: tert-butyl N-[1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]carbamate
• CAS: 1279834-93-3
• 化学式: C₁₅H₂₀F₃N₃O₂
• mdl: MFCD09834012
• 分子量: 331.33
• InChiKey: DVJBBFSJUNMEHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
  申请人：Rami Harshad Kantilal

  公开号：US20090163506A1

  公开（公告）日：2009-06-25

  Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R 1 , R 2 , P, P′, n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  某些式(I)的化合物，或其药学上可接受的盐，或其溶剂化物，其中R1、R2、P、P′、n、p、q、r和s的定义如规范所述，制备这种化合物的过程，包括这种化合物的药物组成物，以及这种化合物和组成物在医学上的使用。
• Urea compounds active as vanilloid receptor antagonist for the treatment of pain
  申请人：Glaxo Group Limited

  公开号：EP2036902A2

  公开（公告）日：2009-03-18

  Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1, R2, P, P', n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  某些式(I)化合物、 或其药学上可接受的盐，或其溶液，其中 R1、R2、P、P'、n、p、q、r 和 s 如说明书中所定义；制备此类化合物的工艺；包含此类化合物的药物组合物；以及此类化合物和组合物在医药中的用途。
• Combinations of a vanilloid antagonist and an nsaid for the treatment of pain
  申请人：Bountra Charanjit

  公开号：US20060093687A1

  公开（公告）日：2006-05-04

  A method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, a vanilloid VR-1 antagonist or a pharmaceutically acceptable derivative thereof and an NSAID or a pharmaceutically acceptable derivative thereof, wherein said VR-1 antagonist or said NSAID may optionally be administered as a sub-maximal amount.

  一种治疗与疼痛有关的病症并减轻相关症状的方法，包括向哺乳动物（包括人）施用类香草素VR-1拮抗剂或其药学上可接受的衍生物和非甾体抗炎药或其药学上可接受的衍生物，其中所述VR-1拮抗剂或所述非甾体抗炎药可选择以亚最大量施用。
• UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN
  申请人：SmithKline Beecham P.L.C.

  公开号：EP1425277A2

  公开（公告）日：2004-06-09
• US7390817B2
  申请人：——

  公开号：US7390817B2

  公开（公告）日：2008-06-24